The company intends to start shipping upon final authorization by the Drug Enforcement Administration.
Divine Skin chairman and CEO Daniel Khesin said since Divine Skin focuses on underserved and niche categories, of course their pain medication will offer patients some benefits that competitors don’t.
"The product will give better pain relief, with a safety profile similar to that of Advil," Khesin said.